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A pilot study of MVP (mitomycin-C, vinblastine and
cisplatin) chemotherapy in small-cell lung cancer
TF Hickish, IE Smith*, MC Nicolson, S Ashley, K Priest, L Spencer, A Norman, G Middleton and MER O'Brien
Lung Unit, Royal Marsden Hospital, Sutton, Surrey, UK
Summary MVP chemotherapy (mitomycin C 8 mgm-2, courses 1,2,4 and 6, vinblastine 6 mgm-2, cisplatin 50 mgm-2) is an active low-toxicity
regimen in non-small-cell lung cancer (NSCLC). Based on the single-agent activity of these agents in SCLC, we have conducted a phase 11 trial
of MVP in SCLC. Fifty chemo-naive patients with SCLC were entered in this trial. There were 33 men and 17 women with median age 66 years
(range 46-83 years); 18 patients had limited disease (LD) and 32 extensive disease (ED). WHO performance status (PS) was: three patients
PS 0, 33 patients PS 1, ten patients PS 2, four patients PS 3. A maximum of six cycles was given in responding patients. On completion of
chemotherapy, patients with LD obtaining complete response (CR)/good partial response (PR) received thoracic irradiation and those obtaining
CR were offered entry into the ongoing MRC Prophylactic Cranial Irradiation Trial. The overall response was 79% with 17% CR and 62% PR.
For LD patients, 38% obtained CR but for ED only one patient achieved CR. Median response duration for LD patients was 8 months and for
ED patients 5 months. Median survival was 10 months for LD patients and 6 months for ED patients. There was complete resolution of
symptoms in 24%, partial improvement in 68%, no change in 2% and progressive symptoms in 6%. As regards toxicity, 24% developed WHO
grade 3/4 neutropenia, 16% grade 3/4 thrombocytopenia and 6% significant hair loss. Two patients died during the first week of treatment with
neutropenic infection. Quality of life using the EORTC questionnaire (QLC-C30) with lung cancer module demonstrated significant
improvements from baseline levels in emotional and cognitive functioning, global QOL, of pain, dyspnoea and cough. MVP, an effective
palliative regimen for NSCLC, is also active against SCLC with low toxicity and merits comparison with more toxic conventional schedules.
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Despite its initial chemo-radiosensitivity, progress in the treatment
of small-cell lung cancer (SCLC) over the last decade has been
disappointing, with more than 80% of patients dying of recurrent
chemoresistant disease within 2 years of diagnosis. Combination
chemotherapy remains the cornerstone of current management of
this disease and two different approaches to its use can be identified.
On the one hand, there is the dose-intensive approach, which
has failed to yield incremental benefits (Harper and Souhami,
1985; Ihde et al, 1986; Klasa et al, 1991) but has now been revis-
ited with the evaluation of growth factors (Woll et al, 1995) or
high-dose chemotherapy with stem cell rescue (Leyvraz et al,
1995). On the other hand, there is the low-toxicity approach in
recognition of the limited impact of the dose-intensive approach
with its concomitant toxicities. The concern with the latter
approach is that this may result in a survival deficit and no partic-
ular quality-of-life advantage (Joss et al, 1995).
Recently we have reported an MVP (mitomycin C, vinblastine and
cisplatin) chemotherapy schedule in advanced non-small-cell lung
cancer emphasizing symptom relief and low toxicity (Ellis et al,
1995a). The objective response rate (32%) was similar to that
achieved in trials of other active regimens, yet only 3% developed
significant alopecia orWHO grade 3/4 nausea and vomiting and69%
had marked alleviation of tumour-related symptoms. Cisplatin and
the vinca alkaloids have single-agent activity in SCLC. Although
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mitomycin C has not been shown to be active as a second-line agent
in phase II trials in SCLC, it displays synergy with cisplatin in vitro
and has been used in combination chemotherapy studies in SCLC
(Murray et al, 1985; McHale and Einhorn, 1986; Inada, 1988; Broder
et al, 1994). Accordingly, our experience with the MVP regimen
encouraged a phase II pilot trial in previously untreated small-cell
lung cancercombined with a quality-of-life assessment.
PATIENTS AND METHODS
Patient characteristics
Fifty sequential previously untreated patients with histologically or
cytologically proven SCLC were entered into this study between
July 1993 and September 1994. Inclusion criteria included normal
full blood count, satisfactory renal function (51Cr EDTA clearance
> 60 ml min-') and liver function (LFTs less than twice upper limit
of normal) and WHO performance status (PS) < 3. Patients with
cerebral metastases were not excluded from the study.
Patient characteristics and sites of disease involvement are
summarized in Table 1. There were 33 men and 17 women. The
median age was 66 years (range 46-83 years). Sixteen patients had
limited disease (LD) and 34 extensive disease (ED) according to
the two-stage system of the Veterans Administration Lung Group.
WHO performance status was as follows: three patients PS 0, 33
patients PS 1, ten patients PS 2, four patients PS 3.
All patients had pretreatment physical examination, plasma elec-
trolytes, urea and creatinine, serum liver function tests, chest radi-
ography (orcomputerized tomography (CT) ofthorax ifdisease not
measurable on chest radiograph), an imaging examination of the
liver (either ultrasound or CT) and 51Cr EDTA clearance. Isotope
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Table 1 Patient characteristics
Number of patients
Sex
Male
Female
Age (years)
Median
(range)
Limited disease
Extensive disease
WHO PS
0
1
2
3
Median PS
50
33
17
66
(46-83)
18
32
3
33
10
4
Table 2 Objective response
Stage Patients CR PR Overall NC PD
response
LD 18 7 10 17 (94) 1 0
ED 30 1 21 22 (73) 7 1
Total 48 8 31 39 (81) 8 1
Numbers in parentheses are percentages. Two patients not evaluable.
Table 3 Overall symptomatic response
Complete resolution of symptoms 28%
Improved symptoms 64%
No change in symptoms 2%
Symptoms worse 6%
Three patients not evaluable
Table 4 Haematological toxicity
WHO grade (% for any course)
0 1-2 3-4
Anaemia 28 54 18
Leucopenia 42 34 24
Thrombocytopenia 68 16 16
Table 5 Non-haematological toxicity
WHO grade (% for any course)
0 1-2 3-4
Infection 58 30 12
Nausea/vomiting 32 58 10
Alopecia 48 46 6
Mucositis 70 30 -
Diarrhoea 88 8 4
Neuropathy 80 20 -
Nephrotoxicity 96 4 -
Constipation 60 38 2
bone scan, bone marrow aspiration and brain CT were only
performed when clinically indicated.
Before each treatment patients had a physical examination, full
blood count and biochemistry and chest radiography performed.
Restaging of chest and upper abdomen and other known sites of
disease was performed after four cycles of treatment or earlier if
clinically indicated.
Treatment
All patients received the following regimen: mitomycin-C 8 mg m-2
i.v. day 1 (given on alternate courses), vinblastine 6 mg m-2
(maximum 10 mg) i.v. day 1 and cisplatin 50 mg m-2 i.v. day 1,
repeated every 21 days. Intravenous pre- and post-treatment hydra-
tion was given with cisplatin according to the Unit's protocol. The
duration of administration was 8 h enabling treatment to be
delivered as a day-case when appropriate. The decision whether
to administer MVP chemotherapy as a day-case or in-patient was
necessarily flexible and depended on factors such as home circum-
stances, availability oftransport and tolerance ofprevious treatment.
Patients received prophylactic anti-emetic therapy with a 5HT3
antagonist and dexamethasone. Renal function was checked with
51Cr EDTA clearance before alternate courses and the dose of
cisplatin reduced as follows: EDTA . 60 ml min-', full dose; 40-
60 ml min-', 25% dose reduction; < 40 ml min-', no treatment with
cisplatin. Our policy at the time of this study was not to use
prophylactic antibiotics. Treatment with MVP chemotherapy was
continued until the development of progressive disease, unaccept-
able toxicity or to a maximum of six cycles in patients achieving
objective response and/or symptomatic relief.
After the completion of chemotherapy, patients under 70 years
of age with limited disease obtaining CR or good PR received
thoracic irradiation to 40 Gy in 15 fractions over 3 weeks. Where
necessary this was given in two phases to keep the spinal cord dose
within tolerance. Patients obtaining CR were offered entry into an
ongoing MRC prophylactic cranial irradiation trial (PCI). Those
patients who received PCI had fractionated whole-brain radio-
therapy to total doses between 24 and 36 Gy.
Response, toxicity and survival analysis
Tumour response was defined according to standard criteria
(Miller et al, 1981). CR was defined as the disappearance of all
clinical, radiological and biochemical evidence of disease for at
least 4 weeks and PR was defined as a reduction in the product of
two diameters of measurable disease by at least 50% for at least 4
weeks, without the appearance of new lesions or progression of
any one lesion. Stable disease (SD/NC) was defined as < 50%
decrease or < 25% increase in the size of the measurable disease,
without the appearance ofnew lesions or progression ofany lesion
> 25% for 1 month. Progressive disease (PD) was defined > 25%
increase in one or more of the measurable lesions of the appear-
ance of a new lesion(s). Toxicity was also graded according to
standard WHO criteria (Miller et al, 1981).
Tumour-related symptoms were recorded at the start of treat-
ment under the following general headings: malaise, pain, cough,
dyspnoea or 'other', which was then specified. Symptoms were
then reassessed independently of the medical team by research
nurses following each course of treatment with patients asked to
grade change in symptoms using simple descriptive criteria as
follows: (1) complete disappearance of symptoms (CR); (2) good
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Figure 1 Survival: limited (-) vs extensive (--- -) disease
Table 6 Symptom response - change from baseline
MVP no. 1 MVP no. 2 MVP no. 3 MVP no. 4
Pain 0.002 0.003 0.025 0.036
Cough 0.001 0.001 0.001 0.001
Dyspnoea 0.001 0.001 0.001 0.001
Malaise 0.003 0.002 0.002 0.005
P-values. Significance calculated using the Mann-Whitney test.
Table 7 Quality of life - change from baseline
QoL item 3 weeks 6 weeks 9 weeks 12 weeks Direction
Physical functioning NS NS NS NS NS
Role functioning NS NS NS NS NS
Emotional functioning 0.037 NS NS 0.022 Better
Cognitive functioning NS NS NS 0.044 Better
Social functioning NS NS NS NS NS
Global QoL 0.005 NS 0.035 NS Better
Fatigue NS NS NS NS NS
Nausea and vomiting NS NS NS NS NS
Pain 0.005 NS 0.041 NS Less
Dyspnoea 0.006 NS 0.022 NS Less
Sleep disturbance NS NS NS NS NS
Appetite loss NS NS NS NS NS
Constipation NS NS NS NS NS
Diarrhoea NS NS NS NS NS
Financial impact NS NS NS NS NS
Lung module
Cough 0.005 0.007 0.196 0.037 Less
Dyspnoea NS NS NS NS NS
Swallowing NS NS NS NS NS
Toxic effects 0.038 0.014 NS NS More
Pain 0.039 NS NS NS Less
P-values for difference from baseline.
improvement of symptoms (PR); (3) minor or no change in symp-
toms (NC); (4) worse (PD).
Response duration and survival were calculated from the date of
first treatment using the standard life-table method of Kaplan and
Meier (Kaplan and Meier, 1958).
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Figure 2 Overall survival for patients treated in this trial (-) and controls
(--- -) matched for age, stage, performance status and disease extent treated
in a series of chemotherapy trials in the Lung Unit at the Royal Marsden
Hospital. Each patient had four matched controls. Details of the
chemotherapy regimens used in these trials are given in the following: Smith
et al (1985, 1987, 1990), Smith (1992), Jones et al (1991, 1993), Ellis et al
(1995b). The chi-squared test was used to detect any difference between the
two survival curves
Quality-of-life assessment
A measurement of quality of life was defined using the European
Organization for Research and Treatment of Cancer (EORTC)
questionnaire (EORTC QLC-C30) with lung cancer module.
Patients were given standard instructions and invited to make
ratings before starting treatment - baseline, and before each subse-
quent cycle ofMVP (i.e. every 3 weeks) and at follow-up after the
completion of treatment. Responses were scored according to the
EORTC QL Group guidelines with conversion to a 0-100 scale
using the recommended algorithm.
Ethics
This study was conducted in accordance with the declaration of
Helsinki and approved by the Royal Marsden Hospital Ethical
Committee. Witnessed informed consent was obtained from all
patients according to guidelines laid down by the Committee.
RESULTS
Of the 50 patients initially entered into this study, 48 were assess-
able for response and all were evaluable for toxicity. Two patients
died during the first week of treatment with neutropenic infection.
All patients were included in survival analysis.
Response
Overall, 38 patients (81%, 95% CI 78-96%) obtained an objective
response with eight CR (17%) and 31 PR (65%). In limited disease
(LD) patients, an overall response rate of94% (95% CI 83-100%)
was obtained with 38% CR. For patients with extensive disease
(ED), 73% (95% CI 66-96%) of patients achieved a response but
only one patient (2%) achieved CR. Details of response by stage
are shown in Table 2. Median response duration from initiation of
chemotherapy for LD patients was 8 months, for ED patients 5
months, with an overall response duration of 5 months. Median
response duration measured from the end ofchemotherapy for LD
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patients was 12 weeks, for ED patients 6 weeks, with an overall
response duration of 7 weeks. Median survival from initiation of
chemotherapy was 10 months for LD patients and 6 months for
ED patients; the overall value being 7 months (Figure 1). Median
survival measured from the end of chemotherapy for LD patients
was 6 months, for ED patients 3 months; the overall value being 4
months.
The overall symptom response was 64%, with 28% of patients
experiencing complete relief of symptoms (Table 3). The change
from baseline was significant for all the major symptoms (pain,
cough, dyspnoea and malaise).
Toxicity
Twenty-four per cent of patients developed WHO grade 3/4
neutropenia (Table 4). There were two deaths associated with
neutropenic infection and these occurred during the first week of
treatment. Sixteen per cent of patients developed grade 3/4
thrombocytopenia at any stage during treatment (Table 4). Non-
haematological toxicity was minimal. Sixty-eight per cent of
patients experienced some degree of nausea and vomiting over the
course of treatment. Just 6% developed alopecia and there was no
significant nephrotoxicity or neurotoxicity (Table 5).
Number of cycles of MVP chemotherapy
The number of cycles per patient of MVP chemotherapy was as
follows: one cycle, five patients; two cycles, seven patients; three
cycles, six patients; four cycles, six patients; five cycles, ten
patients; six cycles, 16 patients.
Dose reductions and delays
Four patients had 25% dose reductions (due to anaemia, one
patient; repeated chest infections, one patient; neutropenia/fever,
one patient; and low EDTA/nephrotoxicity, one patient. Four
patients had dose delays (due to chest infection, one patient;
cellulitis, one patient; infection, one patient; and general malaise
with fever/shivers, one patient).
Quality of life
Quality-of-life baseline data are available for 41 patients and 12-
week follow-up data are available for 25 patients (Table 6 and 7).
Thereafter attrition on quality-of-life data was high with insuffi-
cient data available for analysis. Over the initial 12 weeks of treat-
ment there was improvement in a range of quality-of-life items
that appeared to mirror the symptom response data. There was no
evidence of a deterioration in other quality-of-life measurements.
Database comparison with other chemotherapy
regimens given as first-line therapy for SCLC
We have conducted a survival analysis comparison (Kaplan-Meier
survival curves) of patients entered in this trial with patients
matched for age, stage, performance status and disease extent (ED,
LD) treated in the context of a series of Royal Marsden
chemotherapy trials (Smith et al, 1985, 1987, 1990; Smith, 1992;
Jones et al, 1991, 1993; Ellis et al, 1995b). Each patient in the
current trial had four matched controls. There was no difference in
the survival between the two groups (P> 0.1) (Figure 2).
DISCUSSION
This study demonstrates that a moderate-dose MVP regimen is
active in SCLC and combines the benefits of symptom relief and
mild toxicity seen with its use in NSCLC (Ellis et al, 1995a).
The response rate and survival data for this pilot trial are similar
to those from other reported series using platinum/etoposide and
doxorubicin-based regimens (Ellis et al, 1995b; Bishop et al, 1987;
Evans et al, 1988; Fukuoka et al, 1991; Roth et al, 1992). There
was no survival difference between patients entered in this trial
and matched controls treated in a series of chemotherapy trials
with data entered prospectively on our database (Figure 2).
For survival, these data are less impressive than the median
survival data reported with dose-intensive regimens supported
with growth factors or peripheral stem cell transplantation in the
treatment of selected patients (Brugger et al, 1995; Woll et al,
1995; Fetscher et al, 1997). In a recent update of a non-random-
ized study evaluating multimodality therapy including high-dose
chemotherapy with peripheral stem cell transplantation, a survival
advantage for this approach appeared to accrue to young, good
performance status, LD patients (Fetscher et al, 1997). To date,
only one small randomized trial has compared conventional dose
chemotherapy with high-dose chemotherapy supported by stem
cell rescue (in this case ABMT), and this demonstrated improved
disease-free survival in the high-dose arm (Humblet et al, 1987).
As such, a dose-intensive approach may yield a survival advantage
for selected patients and, for these, MVP chemotherapy would
represent undertreatment.
However, forolder, poor performance status/ED patients, reduc-
tion in toxicity with maintenance (ideally with improvement) of
the survival fraction is the current goal of trials. The possibility
that a 'more gentle' chemotherapy regimen may have inadequate
activity in SCLC was demonstrated in a recent trial in which
patients with advanced disease were randomized to receive either
weekly carboplatin and teniposide or cisplatin, doxorubicin and
etoposide alternating with cyclophosphamide, methotrexate,
vincristine and lomustine (Joss et al, 1995). The trial was closed
before the planned accrual because of a significant survival differ-
ence in favour of the more intensive alternating regimen (1 year
survival: 30% vs 4%). Toxicity was greater with the more inten-
sive regimen but there was no difference found in patient-related
tumour symptoms or general quality-of-life categories. Likewise,
that a regimen initially conceived to have low toxicity with accept-
able anti-tumour activity may not do so is exemplified by the
MRC randomized trial of oral etoposide in comparison to intra-
venous multidrug chemotherapy (Girling et al, 1996). In this trial,
the oral etoposide schedule was associated with greater toxicity
and a poorer median survival. However, another MRC randomized
trial of a two-drug regimen (EV: etoposide, vincristine) with a
four-drug regimen (ECMV: etoposide, cyclophosphamide,
methotrexate, vincristine) for poor performance status patients
demonstrated how toxicity can be reduced significantly without a
survival deficit (Bleehen et al, 1996).
The anti-tumour response achieved with the MVP regimen in
this trial was matched by symptom relief and patients overall had
an improvement in a range of quality-of-life items (during the
initial 12 weeks of treatment), as measured by the EORTC Quality
of Life Assessment instrument.
As we have reported previously (Ellis et al, 1995a), this MVP
regimen has a low cost. Furthermore it is pragmatic and represents
a reasonable alternative when diagnostic uncertainties arise and
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the tumour cannot be confidently defined as small-cell or non-
small-cell.
Moderate-dose MVP chemotherapy has acceptable anti-tumour
activity and toxicity in small-cell lung cancer. It offers an appro-
priate comparator in future randomized trials for poorperformance
status patients in which minimization oftoxicity and enhancement
ofquality oflife are emphasized.
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